drugset / Trial / NCT06152978
A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
Phase 2
Not yet recruiting
182 enrolled
Fudan University
Innovent Biologics (Suzhou) Co. Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is aimed to evaluate the efficacy and safety of sintilimab combined with chemotherapy versus chemotherapy in perioperative treatment of locally advanced esophageal squamous cell carcinoma.
Timeline
- Start
- 2023-12-15
- Primary completion
- 2025-12-15
- Completion
- 2027-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Nab-paclitaxel | Small molecule | 260 mg/m2 | Intravenous |